Vviloxazine (Qelbree), is a new treatment option for attention-deficit hyperactivity disorder (ADHD), approved in the United States in April 2021. This drug is a norepinephrine reuptake inhibitor indicated for patients aged 6 to 17 years with ADHD.

It is taken once a day, with or without food. It may cause drowsiness, so these patients should not operate heavy machinery while taking this medication, until they know how they will react. Viloxazine can cause decreased appetite, irritability, nausea, tiredness, trouble sleeping, and vomiting.

It is available in dosages of 100, 150, and 200mg. Finally, concomitant use of this drug with monoamine oxidase inhibitors and cytochrome P450 1A2 substrates are contraindicated.